#Cambridge #United Kingdom #AI Technology #risk management #OPRA Platform

TRI's New OPRA Release: A Game Changer in Risk Management

In a major development for clinical research, Triumph Research Intelligence (TRI) has announced the launch of the latest version of its risk-based quality management (RBQM) platform, OPRA, on October 14, 2026. This upgrade introduces a connected approach to RBQM, aimed at enhancing the quality and oversight of clinical trials. By incorporating AI technologies, TRI is set to transform how teams assess risks and make informed decisions throughout the research process.

Streamlining Risk Assessment with AI

The updated OPRA 26.2 version includes an innovative AI agent named RiskIQ, which operates within the Protocol Insights module. This new addition streamlines the initial risk assessment phase by analyzing uploaded protocols and generating a first-draft assessment of Critical-to-Quality (CtQ) factors and associated risks. One of the most significant advantages of RiskIQ is its adaptability; the AI utilizes an organization’s specific CtQ types and risk categories, tailoring assessments according to their unique requirements and preventing reliance on generic templates.

Team members, particularly risk managers, retain the authority to edit, accept, or reject AI-generated suggestions before publishing the final risk assessment in OPRA. Such a process ensures that no unverified AI content directly enters a live study, promoting accountability and transparent decision-making, which is meticulously recorded and exportable.

Active Oversight and Real-time Monitoring

Beyond mere assessment, OPRA 26.2 turns risk management into an integral aspect of study oversight. The platform links identified risks to the respective Centralized Monitoring controls. This connectivity allows risk owners to instantly monitor any performance issues that may exist outside acceptable parameters. Review-driven actions are directly connected to verifiable evidence, while the Controls Automation feature efficiently generates routine observations, significantly aiding in the oversight process.

Enhanced Collaboration Across Teams

One of the standout features of OPRA is its collaborative framework. Risk managers can easily invite colleagues from different functions to review and provide feedback on CtQs, risks, and suggestions while maintaining responsibility for the final assessment. This functionality minimizes the need for cumbersome off-platform processes, such as spreadsheets, thereby improving efficiency and communication across the board.

Advanced Review Capabilities

The latest OPRA platform allows organizations to define their own review types, such as safety, eligibility, or endpoint reviews. Users can specify which data each review targets, providing clear, structured feedback. The inclusion of change logs will notify reviewers of all modifications made since their previous checks, ensuring they are always up-to-date. This tracking capability is invaluable, enabling medical monitors and Clinical Research Associates (CRAs) to seamlessly pick up from where they left off, thereby demonstrating compliance effectively.

The Future of Clinical Trials

The introduction of OPRA 26.2 represents a significant leap forward in risk-based quality management in clinical trials. By incorporating intelligent AI-driven tools, TRI empowers organizations to conduct more efficient and higher-quality research. This not only enhances the overall research process but also contributes to patient safety and treatment efficacy.

TRI has built a robust reputation over its 13 years of operation, having facilitated over 450 global clinical trials through innovative RBQM practices. The insights gained from TRI's experienced workforce, many of whom have backgrounds in sponsorship or CRO roles, play an integral role in shaping the design and functionality of OPRA.

For more information about TRI and the OPRA platform, visit tritrials.com.